Class IIITerminatedVoluntary: Firm initiated

SUNGAL INC: food recall H-0636-2025

SUNGAL INC of Kearny, NJ recalled UDK ,Half Plum, 170 g, Container, 24, ambient. Reason: Cyclamate adulteration. The FDA listed it as Class III in its Enforcement Report dated Oct 1, 2025; distribution: California, Maryland, New York, Virginia.

Record status as published: Terminated (terminated Dec 8, 2025). openFDA data last updated Oct 21, 2026.

Have this product? Check FDA.gov and your retailer. This page reproduces an FDA Enforcement Report record and is not a public alert. Look for the firm's recall notice on the FDA's recalls page, or ask the store where you bought it what to do. If you think you got sick from a food, contact a health care provider.

Recall details

Product
UDK ,Half Plum, 170 g, Container, 24, ambient
Product quantity
29 CASES
Reason for recall
Cyclamate adulteration
Codes, lots and dates on the package
code 2024 12 15 2 UPC 9588837778794
Distribution pattern
The adulterated product was distributed to the following states: CA, MD, NY, VA
Recalling firm
SUNGAL INC, Kearny, NJ
Classification
Class III — the FDA uses this class for a situation in which using or being exposed to the product is not likely to cause adverse health consequences.
Voluntary or mandated
Voluntary: Firm initiated
How the firm first notified customers
E-Mail

Dates

EventDate
Recall initiated by the firmAug 8, 2025
Classified by the FDASep 23, 2025
Published in the Enforcement ReportOct 1, 2025
TerminatedDec 8, 2025

Other recalls by SUNGAL INC

  • H-0689-2026 · May 13, 2026 · Class II — Product Contains undeclared FD&C Yellow #5 & #6 and Red #40

All food recall records

OpenPlate shows FDA records as published and does not add new findings. Product names and company names belong to their owners.

Sources

  • U.S. Food and Drug Administration, openFDA food enforcement reports, recall number H-0636-2025 (openFDA record). Data provided by the U.S. Food and Drug Administration (https://open.fda.gov).
  • Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service. The FDA does not endorse OpenPlate.